open access

Vol 69, No 3 (2018)
Original papers
Published online: 2018-04-12
Submitted: 2017-12-04
Accepted: 2018-02-01
Get Citation

Adiponectin expression in visceral adiposity is an important determinant of insulin resistance in morbid obesity

Anca Elena Sirbu, Laura Buburuzan, Steliana Kevorkian, Sorina Martin, Carmen Barbu, Catalin Copaescu, Bogdan Smeu, Simona Fica
DOI: 10.5603/EP.a2018.0026
·
Pubmed: 29645064
·
Endokrynologia Polska 2018;69(3):252-258.

open access

Vol 69, No 3 (2018)
Original papers
Published online: 2018-04-12
Submitted: 2017-12-04
Accepted: 2018-02-01

Abstract

Introduction: Visceral adiposity is associated with decreased serum adiponectin levels, peripheral resistance to insulin and an increased risk of cardio-metabolic complications. However, the link between adiponectin expression in visceral adipose tissue (VAT), its serum levels and metabolic protection is controversial. The aim of this study was to investigate the relationship between the adiponectin gene expression in VAT and clinical and metabolic parameters in patients with severe obesity. Material and Methods: This is a cross-sectional study that included 51 severely obese patients (age 43.24±11.29 years, BMI 45.13±8.67 kg/m2), extensively evaluated clinically and biologically (metabolic tests, serum adiponectin measurements, HOMA-IR) before bariatric surgery. Omental adipose tissue was sampled during the intervention and the relative quantification of adiponectin gene expression was performed by real-time PCR, using beta-actin as reference gene. Results. Adiponectin mRNA in VAT was significantly higher in obese insulin-sensitive patients than in the rest of obese patients (p < 0.05) and negatively correlated with HOMA-IR (r =-0.354, p=0.016) and uric acid (r =-0.304, p=0.045). After adjustment for gender, TG/HDL ratio and uric acid, adiponectin expresion (β= -0.439, p=0.001), waist circumference (β=0.467, p=0.001) and serum adiponectin (β =-0.339, p=0.011) remained significantly associated with HOMA-IR, together explaining more than 50% of its variation. Conclusions. In severely obese patients, adiponectin gene expression in VAT is negatively correlated with serum levels of uric acid and is an independent determinant, together with anthropometric parameters of visceral obesity and serum adiponectin levels, of insulin resistance.

Abstract

Introduction: Visceral adiposity is associated with decreased serum adiponectin levels, peripheral resistance to insulin and an increased risk of cardio-metabolic complications. However, the link between adiponectin expression in visceral adipose tissue (VAT), its serum levels and metabolic protection is controversial. The aim of this study was to investigate the relationship between the adiponectin gene expression in VAT and clinical and metabolic parameters in patients with severe obesity. Material and Methods: This is a cross-sectional study that included 51 severely obese patients (age 43.24±11.29 years, BMI 45.13±8.67 kg/m2), extensively evaluated clinically and biologically (metabolic tests, serum adiponectin measurements, HOMA-IR) before bariatric surgery. Omental adipose tissue was sampled during the intervention and the relative quantification of adiponectin gene expression was performed by real-time PCR, using beta-actin as reference gene. Results. Adiponectin mRNA in VAT was significantly higher in obese insulin-sensitive patients than in the rest of obese patients (p < 0.05) and negatively correlated with HOMA-IR (r =-0.354, p=0.016) and uric acid (r =-0.304, p=0.045). After adjustment for gender, TG/HDL ratio and uric acid, adiponectin expresion (β= -0.439, p=0.001), waist circumference (β=0.467, p=0.001) and serum adiponectin (β =-0.339, p=0.011) remained significantly associated with HOMA-IR, together explaining more than 50% of its variation. Conclusions. In severely obese patients, adiponectin gene expression in VAT is negatively correlated with serum levels of uric acid and is an independent determinant, together with anthropometric parameters of visceral obesity and serum adiponectin levels, of insulin resistance.
Get Citation

Keywords

adiponectin expression, visceral adipose tissue, HOMA-IR, insulin resistance, severe obesity

About this article
Title

Adiponectin expression in visceral adiposity is an important determinant of insulin resistance in morbid obesity

Journal

Endokrynologia Polska

Issue

Vol 69, No 3 (2018)

Pages

252-258

Published online

2018-04-12

DOI

10.5603/EP.a2018.0026

Pubmed

29645064

Bibliographic record

Endokrynologia Polska 2018;69(3):252-258.

Keywords

adiponectin expression
visceral adipose tissue
HOMA-IR
insulin resistance
severe obesity

Authors

Anca Elena Sirbu
Laura Buburuzan
Steliana Kevorkian
Sorina Martin
Carmen Barbu
Catalin Copaescu
Bogdan Smeu
Simona Fica

References (27)
  1. Frühbeck G, Toplak H, Woodward E, et al. Executive Committee of the European Association for the Study of Obesity. Obesity: the gateway to ill health - an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts. 2013; 6(2): 117–120.
  2. Kivimäki M, Kuosma E, Ferrie JE, et al. Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe. Lancet Public Health. 2017; 2(6): e277–e285.
  3. Marcadenti A, de Abreu-Silva EO. Different adipose tissue depots: Metabolic implications and effects of surgical removal. Endocrinol Nutr. 2015; 62(9): 458–464.
  4. Mithieux G. Metabolic effects of portal vein sensing. Diabetes Obes Metab. 2014; 16 Suppl 1: 56–60.
  5. Gao He, Fall T, van Dam RM, et al. Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian randomization study. Diabetes. 2013; 62(4): 1338–1344.
  6. Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab. 2014; 28(1): 119–130.
  7. Gastrointestinal Surgery for Severe Obesity. Ann Intern Med. 1991; 115(12): 956.
  8. Sirbu A, Gologan S, Arbanas T, et al. Adiponectin, body mass index and hepatic steatosis are independently associated with IGF-I status in obese non-diabetic women. Growth Horm IGF Res. 2013; 23(1-2): 2–7.
  9. American Diabetes Association. Standards of medical care in diabetes — 2012. Diabetes Care. 2012; 35 Suppl 1: S11–S63.
  10. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412–419.
  11. Amato MC, Giordano C, Galia M, et al. AlkaMeSy Study Group. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010; 33(4): 920–922.
  12. Schmittgen TD, Zakrajsek BA, Mills AG, et al. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem. 2000; 285(2): 194–204.
  13. Turer AT, Khera A, Ayers CR, et al. Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia. 2011; 54(10): 2515–2524.
  14. Han SJ, Boyko EJ, Fujimoto WY, et al. Low Plasma Adiponectin Concentrations Predict Increases in Visceral Adiposity and Insulin Resistance. J Clin Endocrinol Metab. 2017; 102(12): 4626–4633.
  15. Kadowaki T, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and its receptors: implications for obesity-associated diseases and longevity. Lancet Diabetes Endocrinol. 2014; 2(1): 8–9.
  16. Lihn AS, Bruun JM, He G, et al. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol. 2004; 219(1-2): 9–15.
  17. Degawa-Yamauchi M, Moss KA, Bovenkerk JE, et al. Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. Obes Res. 2005; 13(4): 662–669.
  18. Yang WS, Chen MH, Lee WJ, et al. Adiponectin mRNA levels in the abdominal adipose depots of nondiabetic women. Int J Obes Relat Metab Disord. 2003; 27(8): 896–900.
  19. Drapeau V, Lemieux I, Richard D, et al. Metabolic profile in severely obese women is less deteriorated than expected when compared to moderately obese women. Obes Surg. 2006; 16(4): 501–509.
  20. Frederiksen L, Nielsen TL, Wraae K, et al. Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men. J Clin Endocrinol Metab. 2009; 94(10): 4010–4015.
  21. Tonelli J, Li W, Kishore P, et al. Mechanisms of Early Insulin-Sensitizing Effects of Thiazolidinediones in Type 2 Diabetes. Diabetes. 2004; 53(6): 1621–1629.
  22. Banga A, Unal R, Tripathi P, et al. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab. 2009; 296(3): E480–E489.
  23. Zhu Y, Hu Y, Huang T, et al. High uric acid directly inhibits insulin signalling and induces insulin resistance. Biochem Biophys Res Commun. 2014; 447(4): 707–714.
  24. Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011; 60(4): 1258–1269.
  25. Lopes HF, Corrêa-Giannella ML, Consolim-Colombo FM, et al. Visceral adiposity syndrome. Diabetol Metab Syndr. 2016; 8: 40.
  26. Chen J, Spagnoli A, Torquati A. Omental gene expression of adiponectin correlates with degree of insulin sensitivity before and after gastric bypass surgery. Obes Surg. 2012; 22(3): 472–477.
  27. Caselli C. Role of adiponectin system in insulin resistance. Mol Genet Metab. 2014; 113(3): 155–160.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl